Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Milind Y. Desai(Cleveland Clinic), Steven E. Nissen(Cleveland Clinic), Olga Azevedo(British Heart Foundation), Perry Elliott(UCL Australia), Yue Zhong(Bristol-Myers Squibb (United States)), Jonathan Myers, Thomas A. Rano(Bristol-Myers Squibb (United States)), Iacopo Olivotto, Hiroaki Kitaoka(University of Kochi), Lisa Mitchell(Cleveland Clinic), Benjamin Meder(Heidelberg University), Anjali Owens(University of Pennsylvania), Ron Aronson(Bristol-Myers Squibb (United States)), Victoria Florea(Bristol-Myers Squibb (United States)), Nicolas Verheyen(Medical University of Graz), Pablo García‐Pavía(Universidad Francisco de Vitoria), Renato D. Lópes(Duke University), Wael A. Jaber(Cleveland Clinic), Qiuqing Wang(Cleveland Clinic), Zhiqun Gong(Bristol-Myers Squibb (United States)), Kathy Wolski(Cleveland Clinic), Lars S. Maier(University Hospital Regensburg), Fábio Fernandes(University of Illinois Chicago), Suzanne Carter-Bonanza(Bristol-Myers Squibb (United States)), Theodore P. Abraham(University of California, San Francisco)
Cited by 51
Related Papers
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
|New England Journal of Medicine|2007|4.7k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k